DKSH Hong Kong and SINOVAC Sign Partnership to Strengthen CoronaVac®  Network in Hong Kong September 30, 2021


			
				DKSH Hong Kong and SINOVAC Sign Partnership to Strengthen CoronaVac®  Network in Hong Kong

The strategic collaboration will be centered around brining the biopharmaceutical group’s CoronaVac® into Hong Kong’s healthcare market.

Media release

DKSH Hong Kong and SINOVAC Sign Partnership to Strengthen CoronaVac®  Network in Hong Kong

The strategic collaboration will be centered around brining the biopharmaceutical group’s CoronaVac® into Hong Kong’s healthcare market.

Hong Kong, September 30, 2021 – DKSH Business Unit Healthcare, Asia’s leading partner for healthcare companies seeking to grow their business in Asia and beyond, and SINOVAC Biotech (Hong Kong) Ltd. (SINOVAC) jointly announce their strategic partnership to strengthen the scientific education of doctors and healthcare practitioners on the inactivated COVID-19 vaccine CoronaVac®, and also in enhancing the coverage across channels in the healthcare sector in Hong Kong. 

 

CoronaVac® was the first official vaccine to arrive in Hong Kong on February 19, 2021 and has been one of the two official vaccines adopted under the COVID-19 Vaccination Program launched by the Hong Kong Special Administrative Region (HKSAR), since then. On June 1, 2021, the World Health Organization (WHO) granted the vaccine Emergency Use Authorization (EUA) approval. CoronaVac® is one of the most widely usedCOVID-19 vaccines. With almost two billion doses delivered globally, the vaccine is now available in over 50 countries in Africa, Asia, Central America, Eastern Europe, Middle East, and South America. SINOVAC is going to supply a total of 380 million doses of CoronaVac®to COVID-19 Vaccines Global Access (COVAX).

 

During the contract signing ceremony, SINOVAC and DKSH addressed the partnership with confidence and exchanged visions and opinions about the latest research and development of the vaccine and its application in various regions.

 

Ms. Cheryl Law, International Business Development Director, Asia Pacific of SINOVAC, said: "On behalf of SINOVAC, we are delighted to partner with DKSH in the fight against COVID-19, which has hugely impacted every market and region for nearly two years. SINOVAC has dedicated one year of research on the development of CoronaVac® since the beginning of the outbreak. We have driven all resources, manpower, research, and development into this fight and into the development of this vaccine within such a short period of time. In the next phase, we need a trusted and professional partner to reach and educate the local medical practitioners about the importance of vaccination and to provide updates on the latest research and clinical trials made of CoronaVac®, using COVID-19 variants, booster doses, age extension into pediatric population, and other segments.”

 

In his officiating speech, Mr. Fong Wai Ting, Head of Management and Vice President of Healthcare, DKSH Hong Kong & Macau, expressed his appreciation for the partnership: “DKSH Hong Kong is pleased to partner with SINOVAC. Vaccines are crucial, either as an immunity agent or as a preventive agent, against severe medical conditions. This project is a significant step to further engage and expand DKSH’s contribution to the community and to provide people with access to quality healthcare products. We are continuously fulfilling our purpose of “enriching people’s lives.”